Role of Pancreatic Transcription Factors in Maintenance of Mature β-Cell Function

Hideaki Kaneto 1,* and Taka-aki Matsuoka 2

1 Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 577, Matsushima, Kurashiki 701-0192, Japan
2 Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan; E-Mail: matsuoka@endmet.med.osaka-u.ac.jp

* Author to whom correspondence should be addressed; E-Mail: kaneto@med.kawasaki-m.ac.jp; Tel.: +81-86-464-1111; Fax: +81-86-464-1046.

Academic Editor: Florian Lang

Received: 16 December 2014 / Accepted: 16 February 2015 / Published: 18 March 2015

Abstract: A variety of pancreatic transcription factors including PDX-1 and MafA play crucial roles in the pancreas and function for the maintenance of mature β-cell function. However, when β-cells are chronically exposed to hyperglycemia, expression and/or activities of such transcription factors are reduced, which leads to deterioration of β-cell function. These phenomena are well known as β-cell glucose toxicity in practical medicine as well as in the islet biology research area. Here we describe the possible mechanism for β-cell glucose toxicity found in type 2 diabetes. It is likely that reduced expression levels of PDX-1 and MafA lead to suppression of insulin biosynthesis and secretion. In addition, expression levels of incretin receptors (GLP-1 and GIP receptors) in β-cells are decreased, which likely contributes to the impaired incretin effects found in diabetes. Taken together, down-regulation of insulin gene transcription factors and incretin receptors explains, at least in part, the molecular mechanism for β-cell glucose toxicity.

Keywords: pancreatic β-cells; oxidative stress; PDX-1; MafA; GLP-1

1. Role of Pancreatic Transcription Factors in the Pancreas

The adult pancreas is composed of exocrine (acini and ducts) and endocrine compartments (α-, β-, δ-, ε-, and PP-cells). Each of the five endocrine cell types synthesizes and secretes one hormone:
glucagon (α-cells), insulin (β-cells), somatostatin (δ-cells), ghrelin (ε-cells), and pancreatic polypeptide (PP-cells). It has been shown that various pancreatic transcription factors are involved in pancreas development and β-cell differentiation. Pancreatic and duodenal homeobox factor-1 (PDX-1) (also known as IDX-1/STF-1/IPF1) [1–3] and Hb9, both of which are members of the large family of homeodomain (HD)-containing proteins, play a crucial role in the early stage of pancreas development. While PDX-1 affects the development of the entire pancreas [4–13], Hb9 plays an important role for the development of the dorsal pancreas [14,15] (Figure 1). Other subclasses of homeodomain (HD) proteins such as Arx, the LIM domain protein Isl-1, the paired domain proteins Pax4 and Pax6, and the Nkx class proteins Nkx6.1 and Nkx2.2 also play an important role in pancreas development [16–27]. Pancreas-related phenotype in knockout mice of each homeodomain protein is as follows: Arx (−/−), absence of α-cells and increase of β- and δ-cells [27]; Isl-1 (−/−), absence of islet cells [16]; Pax4 (−/−), absence of β-cells, decrease of δ-cells, and increase of α- and ε-cells [17,24]; Pax6 (−/−), absence of α-cells, decrease of β-, δ- and PP-cells, increase of ε-cells [18,19,25]; Nkx6.1 (−/−), decrease of β-cells; Nkx2.2 (−/−), absence of β-cells, decrease of α- and PP-cells, and increase of ε-cells [20,21,24] (Figure 1). In addition, it is noted that Arx and Pax4 are up-regulated in Pax4 (−/−) and Arx (−/−) mice, respectively, in endocrine precursor cells, and thereby these two transcription factors are likely to play opposite roles for proper endocrine specification [27].

| Transcription Factor | Expression in Mature Islets | Pancreas-related Phenotype in Knockout Mice |
|----------------------|-----------------------------|---------------------------------------------|
| PDX-1                | β- and δ-cells              | absence of pancreas                         |
| Hb9                  | β-cells                     | absence of dorsal pancreas                  |
| Isl-1                | all islet cells             | absence of islet cells and dorsal pancreatic mesoderm |
| Pax4                 | not detected                | absence of β- and δ-cells increase of α- and ε-cells |
| Pax6                 | all islet cells             | absence of α-cells decrease of β- δ- and PP-cells increase of ε-cells |
| Nkx2.2               | α-, β- and PP-cells         | absence of β-cells decrease of α- and PP-cells |
| Nkx6.1               | β-cells                     | decrease of β-cells                         |
| Ngn3                 | not detected                | absence of endocrine cells                  |
| NeuroD               | all islet cells             | decrease of endocrine cells                 |
| MafA                 | β-cells                     | decrease of insulin biosynthesis and secretion |

Figure 1. Pancreas-related phenotype in knockout mice of each pancreatic transcription factor.

It is well known that PDX-1 plays a crucial role in pancreas development [4–12], β-cell differentiation [28–38], and maintenance of mature β-cell function by regulating several β-cell-related genes [39–47]. At an early stage of embryonic development, PDX-1 is initially expressed in the gut
region when the foregut endoderm becomes committed to common pancreatic precursor cells. PDX-1 expression is maintained in precursor cells during pancreas development but becomes restricted to β-cells in mature pancreas (Figure 2). In mice homozygous for a targeted mutation in PDX-1, pancreas formation is not observed [4], indicating that PDX-1 plays a crucial role for the formation of endocrine and exocrine cells. Loss of PDX-1 function resulted in pancreatic agenesis in humans as well as in mice [9]. Differentiation and maintenance of the β-cell phenotype also requires PDX-1. In mature β-cells, PDX-1 transactivates the insulin gene and other genes involved in glucose sensing and metabolism such as GLUT2 and glucokinase [42,43]. It was also reported that PDX-1 (+/−) mice were glucose intolerant, with increased islet apoptosis, a decreased islet mass, and abnormal islet architecture, indicating that gene dosage for PDX-1 is crucial for normal glucose homeostasis [10,43,45]. These findings are concordant with the report that humans heterozygous for an inactivating mutation of PDX-1 cause maturity-onset diabetes in the young (MODY 4) [48]. It is noted here, however, that dominant monogenic MODY4 mutations in the PDX-1 gene in humans are not necessarily equivalent to PDX-1 heterozygosity in mice or humans, because it has been reported that recessive mutations in the PDX-1 gene also lead to susceptibility to Type 2 diabetes in humans [49–52]. Furthermore, to explore a role of PDX-1 in the formation and maintenance of the pancreas, genetically engineered mice were developed using the Tet-off system so that the only source of PDX-1 is a transgene that can be controlled by tetracycline or doxycycline [12]. Since in these mice the coding region of the endogenous PDX-1 gene is replaced with that for the tetracycline-regulated transactivator (tTA), in the absence of doxycycline, tTA activates the transcription of a transgene encoding PDX-1. Expression of the transgene-encoded PDX-1 rescued the PDX-1-null phenotype, and doxycycline-mediated repression of the transgenic PDX-1 throughout gestation recapitulated the PDX-1 null phenotype. Doxycycline treatment at mid-pancreogenesis blocked further development [12]. Also, when PDX-1 expression was shut off with doxycycline in adult mice, insulin biosynthesis was decreased and glucose homeostasis was disturbed [12]. These data further strengthen the importance of PDX-1 in pancreas development, β-cell differentiation, and maintenance of mature β-cell function.

The other well-represented class of transcription factors is that of the basic helix loop helix (bHLH) proteins, which include NeuroD and neurogenin3 (Ngn3). NeuroD, a member of the bHLH transcription factor family, also known as BETA2, is expressed in pancreatic and intestinal endocrine cells and neural tissues. NeuroD plays an important role in pancreas development and in regulating insulin gene transcription [53–56]. Mice homozygous for the null mutation in NeuroD have a striking reduction in the number of β-cells, develop severe diabetes and die perinatally [57] (Figure 1). Furthermore, it has been reported that the insulin enhancer elements, E-box (NeuroD binding site) and A-box (PDX-1 binding site), are very important for insulin gene transcription [57,58]. Neurogenin3 (Ngn3), a member of the basic helix-loop-helix (bHLH) transcription factor family, is involved in endocrine differentiation [59–65]. After bud formation, Ngn3 is transiently expressed in endocrine precursor cells, and functions as a potential initiator of endocrine differentiation. Transgenic mice overexpressing Ngn3 show a marked increase in endocrine cell formation, indicating that Ngn3 induces islet cell precursors to differentiate [60,61]. In contrast, mice with targeted disruption of Ngn3 have no endocrine cells [62] (Figure 1).
Figure 2. Pancreatic transcription factor hierarchy during pancreas development. It is well known that many transcription factors are involved in pancreas formation and β-cell differentiation. Among the various transcription factors, PDX-1 plays a crucial role in pancreas formation and β-cell differentiation, and maintenance of mature β-cell function. Ngn3 and NeuroD are also important transcription factors for pancreatic endocrine cell differentiation. MafA expression is induced at the final stage of β-cell differentiation and functions as a potent activator of insulin gene transcription.

It was known that an unidentified β-cell-specific nuclear factor bound to a conserved cis-regulatory element called RIPE3b1 in the insulin gene enhancer region and functioned as an important transactivator for the insulin gene [66,67]. This important transactivator was identified as MafA, a basic-leucine zipper (bLZ) transcription factor [68–70]. MafA controls β-cell-specific expression of the insulin gene through a cis-regulatory element called RIPE3b1 and functions as a potent transactivator for the insulin gene [68–75]. During pancreas development, MafA expression is first detected at the beginning of the principal phase of insulin-producing cell production while other important transcription factors such as PDX-1 and NeuroD are expressed from the early stage of pancreas development (Figure 2). In addition, while both PDX-1 and NeuroD are expressed in various cell types in islets, MafA is expressed only in β-cells and functions as a potent activator of insulin gene transcription. Thus, the potency of MafA as an insulin gene activator, together with its unique expression in β-cells, raises the likelihood that MafA is the principal factor required for β-cell formation and function. Furthermore, it was reported that MafA knockout mice displayed glucose intolerance and developed diabetes mellitus [72]. In MafA (−/−) mice, expression of insulin 1, insulin 2, PDX-1, NeuroD, and GLUT2 was decreased, and glucose-, arginine-, and KCl-stimulated insulin secretion was severely impaired (Figure 1). The MafA (−/−) mice also displayed age-dependent pancreatic islet abnormalities [72]. These results strengthen the importance of MafA in the maintenance of mature β-cell function.
2. Involvement of Pancreatic Transcription Factors in β-Cell Glucose Toxicity

It is well known that pancreatic β-cells secrete insulin when blood glucose levels become high. However, when β-cells are chronically exposed to hyperglycemia, β-cell function gradually deteriorates, which leads to the aggravation of type 2 diabetes. Once hyperglycemia becomes apparent, β-cell function such as insulin biosynthesis and secretion progressively deteriorates. This process is known as β-cell glucose toxicity which is often observed under diabetic conditions. In the diabetic state, hyperglycemia per se and subsequent induction of oxidative stress decrease insulin biosynthesis and secretion and finally bring about apoptosis [76–97].

Under diabetic conditions, oxidative stress is induced through various pathways and involved in β-cell glucose toxicity. β-Cells express GLUT2, a high-Km glucose transporter, and thereby display highly efficient glucose uptake when exposed to a high glucose concentration. Indeed, it was shown that expression levels of oxidative stress markers such as 8-hydroxy-2'-deoxyguanosine (8-OHdG) and 4-hydroxy-2,3-nonenal (4-HNE) were increased in islets under diabetic conditions [81,83]. In addition, β-cells are rather vulnerable to oxidative stress due to the relatively low expression of antioxidant enzymes such as catalase, and glutathione peroxidase. Therefore, it is likely that oxidative stress is involved in the deterioration of β-cell function found in diabetes. It was shown that when β-cell-derived cell lines or isolated islets were exposed to oxidative stress, insulin gene promoter activity and mRNA expression were suppressed [87–96]. In addition, when they were exposed to oxidative stress, bindings of pancreatic transcription factors PDX-1 and/or MafA to the insulin gene promoter were reduced. Furthermore, it was shown that the decrease of insulin gene expression after chronic exposure to a high glucose concentration was prevented by treatment with antioxidants [81,86,92,93]. Reduction of expression and/or DNA binding activities of PDX-1 and/or MafA by chronic exposure to high glucose was also prevented by antioxidant treatment. These results suggest that chronic hyperglycemia suppresses insulin biosynthesis and secretion by increasing oxidative stress, accompanied by reduction of expression and/or DNA binding activities of two important pancreatic transcription factors PDX-1 and MafA. Therefore, it is likely that the alteration of such transcription factors explains, at least in part, the suppression of insulin biosynthesis and secretion, and thereby is involved in β-cell glucose toxicity (Figure 3).

It has been suggested that activation of the c-Jun N-terminal kinase (JNK) pathway is involved in pancreatic β-cell dysfunction found in type 2 diabetes. It was reported that activation of the JNK pathway is involved in reduction of insulin gene expression by oxidative stress and that suppression of the JNK pathway can protect β-cells from oxidative stress [96]. When isolated islets were exposed to oxidative stress, the JNK pathway was activated, preceding the decrease of insulin gene expression. Adenoviral overexpression of dominant-negative type JNK1 (DN-JNK) protected insulin gene expression and secretion from oxidative stress. These results were correlated with change in the binding of PDX-1 to the insulin gene promoter. Adenoviral overexpression of DN-JNK preserved PDX-1 DNA binding activity in the face of oxidative stress, while wild type JNK overexpression decreased PDX-1 DNA binding activity [96]. Taken together, it is likely that activation of the JNK pathway leads to decreased PDX-1 activity and consequent suppression of insulin gene transcription found in the diabetic state. Also, it was shown that PDX-1 was transported from the nuclei to the cytoplasm in response to oxidative stress [97]. Suppression of the JNK pathway inhibited the oxidative
stress-induced PDX-1 translocation, suggesting that activation of the JNK pathway is involved in PDX-1 translocation by oxidative stress. Taken together, it is likely that oxidative stress induces nucleo-cytoplasmic translocation of PDX-1 through activation of the JNK pathway, which leads to reduction of its DNA binding activity and suppression of insulin biosynthesis (Figure 3).

**Figure 3.** Possible molecular mechanism for suppression of insulin biosynthesis in type 2 diabetes. Under diabetic conditions, hyperglycemia induces oxidative stress and thereby leads to suppression of insulin biosynthesis and secretion, which is accompanied by reduction of nuclear PDX-1 and MafA expression. Therefore, it is likely that induction of oxidative stress and suppression of nuclear PDX-1 and MafA expression are involved in β-cell glucose toxicity found in type 2 diabetes.

It is known that c-Jun protein level and activity are increased in response to oxidative stress in various cells [98,99]. We recently reported that c-Jun expression was not clearly detected in islets of control m/m mice, but that the number of c-Jun-positive cells gradually increased with age in the islets of diabetic db/db mice [100]. This expression pattern of c-Jun paralleled the loss of insulin gene transcription factor MafA expression; while c-Jun mRNA level was significantly increased, both MafA and insulin mRNA levels were markedly decreased with age [100]. These results imply that the increased level of c-Jun caused a decrease in MafA and insulin gene expression in old diabetic mice. Furthermore, in immunostaining, in db/db mice nuclear MafA expression in pancreatic islets was markedly decreased with age and was not clearly detected in old mice [100]. In db/db mice insulin expression was also decreased in some cells in which MafA was undetectable or weakly expressed. Furthermore, MafA and insulin expression was suppressed in most c-Jun-positive cells. Similarly, in islets of diabetic KKAy mice, the number of c-Jun-positive cells was increased with marked hyperglycemia, and both MafA and insulin protein levels were decreased in those cells [100]. These
findings suggest that c-Jun is involved in the suppression of MafA and insulin expression under diabetic conditions. In addition, c-Jun overexpression markedly decreased insulin promoter activity, which was consistent with previous reports [101,102] (Figure 3).

Although c-Jun protein expression was almost undetectable in MIN6 cells, adenoviral c-Jun overexpression markedly suppressed MafA protein level and its DNA-binding activity in MIN6 cells [100]. Adenoviral overexpression of c-Jun in isolated mouse islets also markedly suppressed MafA mRNA and protein levels. Consistent with these results, insulin mRNA and protein levels were suppressed by c-Jun overexpression in both MIN6 cells and islets [100]. These findings directly demonstrate that c-Jun suppresses the expression of both MafA and insulin. In addition, since MafA appears to not only regulate insulin expression but also to be involved in insulin secretion [72,75], it is likely that the suppression of MafA protein levels by c-Jun leads to insulin secretory defects that are often observed under diabetic conditions. In conclusion, the augmented expression of c-Jun in diabetic islets decreases MafA activity followed by reduced insulin biosynthesis and secretion, and thereby explains, at least in part, the molecular mechanism for β-cell glucose toxicity that is often observed in type 2 diabetes (Figure 3).

3. Involvement of Incretin Signaling in β-Cell Glucose Toxicity

The incretin effect causes more insulin to be secreted when glucose is orally taken compared to when given intravenously even when blood glucose levels have the same profile. This effect is thought to be very important for maximizing insulin response during meals thereby limiting postprandial glucose excursions. Two incretins have been identified: glucagon-like peptide 1 (GLP-1) and glucose-dependent insulino tropic peptide (GIP). It is thought that such incretins play an important role in glucose homeostasis by promoting insulin secretion immediately on meal ingestion. It is well known that incretins (GLP-1 and GIP) bind their incretin receptors (GLP-1 and GIP receptors) in β-cells and increase intracellular cAMP levels, leading to stimulation of insulin secretion through PKA and/or cAMP-GEF II pathways, suppression of β-cell apoptosis through phosphorylation of CREB and increased bcl-2 expression and increase of β-cell growth through phosphorylation of CREB and increased IRS-2 expression (Figure 4).

Although plasma GLP-1 and GIP levels after meals are almost normal in type 2 diabetes, striking abnormalities are observed in the action of incretin hormones in type 2 diabetes [103]. It was reported that GLP-1 and GIP receptor expression was decreased in a glucose-dependent manner in islets isolated from 90% pancreatectomized diabetic (Px) rats [104]. Such decrease was not observed after normalization of blood glucose levels with phlorizin, which is known to lower blood glucose levels by preventing glucose reabsorption from the glomerular filtrate in the kidney. These results suggest that hyperglycemia per se leads to down-regulation of GLP-1 and GIP receptor expression. Furthermore, insulin response to GLP-1 or GIP was markedly reduced in islets isolated from diabetic rats compared to those from control rats [104]. These results indicate that down-regulation of GLP-1 and GIP receptor expression leads to the deterioration of β-cell function. Similar results were reported in obese type 2 diabetic db/db mice; incretin receptor expression in islets was markedly decreased at 16 weeks of age in db/db mice but was preserved by normalization of blood glucose levels with insulin therapy [105]. Furthermore, down-regulation of GLP-1 receptor expression was observed in type 2
diabetic subjects as observed in diabetic rodents [106]. These results strengthen the hypothesis that hyperglycemia *per se* leads to down-regulation of GLP-1 and GIP receptor expression. In addition, it has been shown that GLP-1 and GIP expression is down-regulated by lipotoxicity; when islets are exposed to high free fat acids, GLP-1 and GIP expression is decreased [107] (Figure 5).

**Figure 4.** Role of incretin signaling in mature β-cells.

**Figure 5.** Down-regulation of incretin receptors in pancreatic β-cells under diabetic conditions. Under diabetic conditions, expression of incretin receptors (GLP-1 and GIP receptors) in β-cells are down-regulated, leading to decrease of insulin secretion, increase of β-cell apoptosis and decrease of β-cell growth. Therefore, it is likely that down-regulation of incretin receptor expression is involved in β-cell glucose toxicity found in type 2 diabetes.
It is well known that transcription factor TCF7L2 is closely associated with type 2 diabetes and plays an important role in glucose metabolism [108–116]. Human genetics studies have revealed that common variants of the TCF7L2 gene are strongly associated with type 2 diabetes mellitus [108–111]. Furthermore, recent reports clearly demonstrated that TCF7L2 plays a crucial role in the maintenance of pancreatic β-cell function [113–116]. Interestingly, it was reported that such TCF7L2 is involved in down-regulation of GLP-1 receptor expression found in diabetes [105]. Indeed, it was shown that expression level of the GLP-1 receptor was lower in isolated human islets treated with siRNA to TCF7L2. Insulin secretion stimulated by glucose or GLP-1 was also impaired in isolated human islets treated with siRNA to TCF7L2 [105]. Furthermore, recent studies have clearly shown that GLP-1 receptor expression level is down-regulated by inactivation or deficiency of TCF7L2 in β-cells [115,116]. Taken together, we think that the down-regulation of incretin receptors by hyperglycemia is largely responsible for the impaired incretin effects and thus, at least in part, explains the molecular mechanism for β-cell dysfunction found in diabetes (Figure 5).

Author Contributions

Hideaki Kaneto and Taka-aki Matsuoka performed research and wrote this manuscript.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Ohlsson, H.; Karlsson, K.; Edlund, T. IPF1, a homeodomain-containing-transactivator of the insulin gene. *EMBO J.* 1993, 2, 4251–4259.
2. Miller, C.P.; McGehee, R.E.; Habener, J.F. IDX-1: A new homeodomain transcription factor expressed in rat pancreatic islets and duodenum that transactivates the somatostatin gene. *EMBO J.* 1994, 13, 1145–1156.
3. Leonard, J.; Peers, B.; Johnson, T.; Ferreri, K.; Lee, S.; Montminy, M.R. Characterization of somatostatin transactivating factor-1, a novel homeobox factor that stimulates somatostatin expression in pancreatic islet cells. *Mol. Endocrinol.* 1993, 7, 1275–1283.
4. Jonsson, J.; Carlsson, L.; Edlund, T.; Edlund, H. Insulin-promoter-factor 1 is required for pancreas development in mice. *Nature* 1993, 37, 606–609.
5. Guz, Y.; Montminy, M.R.; Stein, R.; Leonard, J.; Gamer, L.W.; Wright, C.V.; Teitelmen, G. Expression of murine STF-1, a putative insulin gene transcription factor, in beta cells of pancreas, duodenal epithelium and pancreatic exocrine and endocrine progenitors during ontogeny. *Development* 1995, 121, 11–18.
6. Ahlgren, U.; Jonsson, J.; Edlund, H. The morphogenesis of the pancreatic mesenchyme is uncoupled from that of the pancreatic epithelium in IPF1/PDX1-deficient mice. *Development* 1996, 122, 1409–1416.
7. Offield, M.F.; Jetton, T.L.; Labosky, P.; Ray, M.; Stein, R.W.; Magnuson, M.A.; Hogan, B.L.; Wright, C.V. PDX-1 is required for pancreas outgrowth and differentiation of the rostral duodenum. *Development* 1996, 122, 983–985.
8. Kaneto, H.; Miyagawa, J.; Kajimoto, Y.; Yamamoto, K.; Watada, H.; Umayahara, Y.; Hanafusa, Y.; Matsuzawa, Y.; Yamasaki, Y.; Higashiyama, S.; et al. Expression of heparin-binding epidermal growth factor-like growth factor during pancreas development: A potential role of PDX-1 in the transcriptional activation. *J. Biol. Chem.* 1997, 272, 29137–29143.

9. Stoffers, D.A.; Zinkin, N.T.; Stanojevic, V.; Clarke, W.L.; Habener, J.F. Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. *Nat. Genet.* 1997, 15, 106–110.

10. Dutta, S.; Bonner-Weir, S.; Montminy, M.; Wright, C. Regulatory factor linked to late-onset diabetes? *Nature* 1998, 392, 560.

11. Stoffers, D.A.; Heller, R.S.; Miller, C.P.; Habener, J.F. Developmental expression of the homeodomain protein IDX-1 mice transgenic for an IDX-1 promoter/LacZ transcriptional reporter. *Endocrinology* 1999, 140, 5374–5381.

12. Holland, A.M.; Hale, M.A.; Kagami, H.; Hammer, R.E.; MacDonald, R.J. Experimental control of pancreatic development and maintenance. *Proc. Natl. Acad. Sci. USA* 2002, 99, 12236–12241.

13. Melloul, D. Transcription factors in islet development and physiology: Role of PDX-1 in beta-cell function. *Ann. N. Y. Acad. Sci.* 2004, 1014, 28–37.

14. Harrison, K.A.; Thaler, J.; Pfaff, S.L.; Gu, H.; Kehrl, J.H. Pancreas dorsal lobe agenesis and abnormal islets of Langerhans in Hlxb9-deficient mice. *Nat. Genet.* 1999, 23, 71–75.

15. Li, H.; Arbey, S.; Jessell, T.M.; Edlund, H. Selective agenesis of the dorsal pancreas in mice lacking homeobox gene Hlxb9. *Nat. Genet.* 1999, 23, 67–70.

16. Ahlgren, U.; Pfaff, S.L.; Jessell, T.M.; Edlund, T.; Edlund, H. Independent requirement for ISL1 in formation of pancreatic mesenchyme and islet cells. *Nature* 1997, 385, 257–260.

17. Sosa-Pineda, B.; Chowdhury, K.; Torres, M.; Oliver, G.; Gruss, P. The Pax4 gene is essential for differentiation of insulin-producing beta cells in the mammalian pancreas. *Nature* 1997, 386, 399–402.

18. St-Onge, L.; Sosa-Pineda, B.; Chowdhury, K.; Mansouri, A.; Gruss, P. Pax6 is required for differentiation of glucagon-producing alpha-cells in mouse pancreas. *Nature* 1997, 387, 406–409.

19. Sander, M.; Neubuser, A.; Kalamaras, J.; Ee, H.C.; Martin, G.R.; German, M.S. Genetic analysis reveals that PAX6 is required for normal transcription of pancreatic hormone genes and islet development. *Genes Dev.* 1997, 11, 1662–1673.

20. Sander, M.; Sussel, L.; Connors, J.; Scheel, D.; Kalamaras, J.; Dela Cruz, F.; Schwitzgebel, V.; Hayes-Jordan, A.; German, M. Homeobox gene Nkx6.1 lies downstream of Nkx2.2 in the major pathway of beta-cell formation in the pancreas. *Development* 2000, 127, 5533–5540.

21. Sussel, L.; Kalamaras, J.; Hartigan-O’Connor, D.J.; Meneses, J.J.; Pedersen, R.A.; Rubenstein, J.L.; German, M.S. Mice lacking the homeodomain transcription factor Nkx2.2 have diabetes due to arrested differentiation of pancreatic beta cells. *Development* 1998, 125, 2213–2221.

22. Fujitani, Y.; Kajimoto, Y.; Yasuda, T.; Matsuoka, T.; Kaneto, H.; Umayahara, Y.; Fujita, N.; Watada, H.; Miyazaki, J.; Yamasaki, Y.; et al. Identification of a portable repression domain and an E1A-responsive activation domain in Pax 4: A possible role of Pax 4 as a transcriptional repressor in the pancreas. *Mol. Cell. Biol.* 1999, 19, 8281–8291.
23. Smith, S.B.; Ee, H.C.; Conners, J.R.; German, M.S. Paired-homeodomain transcription factor PAX4 acts as a transcriptional repressor in early pancreatic development. *Mol. Cell. Biol.* **1999**, *19*, 8272–8280.

24. Prado, C.L.; Pugh-Bernard, A.E.; Elghazi, L.; Sosa-Pineda, B.; Sussel, L. Ghrelin cells replace insulin-producing β cells in two mouse model of pancreas development. *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 2924–2929.

25. Heller, R.S.; Jenny, M.; Collombat, P.; Mansouri, A.; Tomasetto, C.; Madsen, O.D.; Mellitzer, G.; Gradwohl, G.; Serup, P. Genetic determinants of pancreatic β-cell development. *Dev. Biol.* **2005**, *286*, 217–224.

26. Pedersen, J.K.; Nelson, S.B.; Jorgensen, M.C.; Henseleit, K.D.; Fujitani, Y.; Wright, C.V.; Sander, M.; Serup, P. Endodermal expression of Nkx6 genes depends differentially on Pdx1. *Dev. Biol.* **2005**, *288*, 487–501.

27. Collombat, P.; Mansouri, A.; Hecksher-Sorensen, J.; Serup, P.; Krull, J.; Gradwohl, G.; Gruss, P. Opposing actions of Arx and Pax4 in endocrine pancreas development. *Genes Dev.* **2003**, *17*, 2591–2603.

28. Ferber, S.; Halkin, A.; Cohen, H.; Ber, I.; Einav, Y.; Goldberg, I.; Barshack, I.; Seijffers, R.; Kopolovic, J.; Kaiser, N.; et al. Pancreatic and duodenal homeobox gene 1 induces expression of insulin genes in liver and ameliorates streptozotocin-induced hyperglycemia. *Nat. Med.* **2000**, *6*, 568–572.

29. Heller, R.S.; Stoffers, D.A.; Bock, T.; Svenstrup, K.; Jensen, J.; Horn, T.; Miller, C.P.; Habener, J.F.; Madsen, O.D.; Serup, P. Improved glucose tolerance and acinar dysmorphogenesis by targeted expression of transcription factor PDX-1 to the exocrine pancreas. *Diabetes* **2001**, *50*, 1553–1561.

30. Kojima, H.; Nakamura, T.; Fujita, Y.; Kishi, A.; Fujimiya, M.; Yamada, S.; Kudo, M.; Nishio, Y.; Maegawa, H.; Haneda, M.; et al. Combined expression of pancreatic duodenal homeobox 1 and islet factor 1 induces immature enterocytes to produce insulin. *Diabetes* **2002**, *51*, 1398–1408.

31. Yoshida, S.; Kajimoto, Y.; Yasuda, T.; Watada, H.; Fujitani, Y.; Kosaka, H.; Gotow, T.; Miyatsuka, T.; Umayahara, Y.; Yamasaki, Y.; et al. PDX-1 induces differentiation of intestinal epithelioid IEC-6 into insulin-producing cells. *Diabetes* **2002**, *51*, 2505–2513.

32. Noguchi, H.; Kaneto, H.; Weir, G.C.; Bonner-Weir, S. PDX-1 protein containing its own Antennapedia-like protein transduction domain can transduce pancreatic duct and islet cells. *Diabetes* **2003**, *52*, 1732–1737.

33. Taniguchi, H.; Yamato, E.; Tashiro, F.; Ikegami, H.; Ogihara, T.; Miyazaki, J. β-Cell neogenesis induced by adenovirus-mediated gene delivery of transcription factor pdx-1 into mouse pancreas. *Gene Ther.* **2003**, *10*, 15–23.

34. Tang, D.-Q.; Cao, L.-Z.; Burkhardt, B.R.; Xia, C.-Q.; Litherland, S.A.; Atkinson, M.A.; Yang, L.-J. *In vivo* and *in vitro* characterization of insulin-producing cells obtained from murine bone marrow. *Diabetes* **2004**, *53*, 1721–1732.
35. Miyatsuka, T.; Kaneto, H.; Kajimoto, Y.; Hirota, S.; Arakawa, Y.; Fujitani, Y.; Umayahara, Y.; Watada, H.; Yamasaki, Y.; Magnuson, M.A.; et al. Ectopically expressed PDX-1 in liver initiates endocrine and exocrine pancreas differentiation but causes dysmorphogenesis. *Biochem. Biophys. Res. Commun.* **2003**, *310*, 1017–1025.

36. Kaneto, H.; Nakatani, Y.; Miyatsuka, T.; Matsuoka, T.; Matsuhsia, M.; Hori, M.; Yamaseaki, Y.; PDX-1/VP16 fusion protein, together with NeuroD or Ngn3, markedly induces insulin gene transcription and ameliorates glucose tolerance. *Diabetes* **2005**, *54*, 1009–1022.

37. Cao, L.-Z.; Tang, D.-Q.; Horb, M.E.; Li, S.-W.; Yang, L.-J. High glucose is necessary for complete maturation of Pdx 1-VP16-expressing hepatic cells into functional insulin-producing cells. *Diabetes* **2004**, *53*, 3168–3178.

38. Imai, J.; Katagiri, H.; Yamada, T.; Ishigaki, Y.; Ogihara, T.; Uno, K.; Hasegawa, Y.; Gao, J.; Ishihara, H.; Sasano, H.; et al. Constitutively active PDX1 induced efficient insulin production in adult murine liver. *Biochim. Biophys. Acta* **2005**, *326*, 402–409.

39. Petersen, H.V.; Serup, P.; Leonard, J.; Michelsen, B.K.; Madsen, O.D. Transcriptional regulation of the human insulin gene is dependent on the homeodomain protein STF1/IPF1 acting through the CT boxes. *Proc. Natl. Acad. Sci. USA* **1994**, *91*, 10465–10469.

40. Peers, B.; Leonard, J.; Sharma, S.; Teitelman, G.; Montminy, M.R. Insulin expression in islet cells relies on cooperative interactions between the helix loop helix factor E47 and the homeobox factor STF-1. *Mol. Endocrinol.* **1994**, *8*, 1798–1806.

41. Waeber, G.; Thompson, N.; Nicod, P.; Bonny, C. Transcriptional activation of the GLUT2 gene by the IPF-1/STF-1/IDX-1 homeobox factor. *Mol. Endocrinol.* **1996**, *10*, 1327–1334.

42. Watada, H.; Kajimoto, Y.; Umayahara, Y.; Matsuoka, T.; Kaneto, H.; Fujitani, Y.; Kamada, T.; Kawamori, R.; Yamasaki, Y. The human glucokinase gene β-cell-type promoter: An essential role of insulin promoter factor 1 (IPF1)/PDX-1 in its activation in HIT-T15 cells. *Diabetes* **1996**, *45*, 1478–1488.

43. Ahlgren, U.; Jonsson, J.; Jonsson, L.; Simu, K.; Edlund, H. β-cell-specific inactivation of the mouse *Ipf1/Pdx1* gene results in loss of the β-cell phenotype and maturity onset diabetes. *Genes Dev.* **1998**, *12*, 1763–1768.

44. Wang, H.; Maechler, P.; Ritz-Laser, B.; Hagenfeldt, K.A.; Ishihara, H.; Philippe, J.; Wollheim, C.B. Pdx1 level defines pancreatic gene expression pattern and cell lineage differentiation. *J. Biol. Chem.* **2001**, *276*, 25279–25286.

45. Brissova, M.; Shiotia, M.; Nicholson, W.E.; Gannon, M.; Knobel, S.M.; Piston, D.W.; Wright, C.V.; Powers, A.C. Reduction in pancreatic transcription factor PDX-1 impairs glucose-stimulated insulin secretion. *J. Biol. Chem.* **2002**, *277*, 1125–1132.

46. Kulkarni, R.N.; Jhala, U.S.; Winnay, J.N.; Krajewski, S.; Montminy, M.; Kahn, C.R. PDX-1 haploinsufficiency limits the compensatory islet hyperplasia that occurs in response to insulin resistance. *J. Clin. Investig.* **2004**, *114*, 828–836.

47. Holland, A.M.; Gonez, L.J.; Naselli, G.; MacDonald, R.J.; Harrison, L.C. Conditional expression demonstrates the role of the homeodomain transcription factor Pdx1 in maintenance and regeneration of beta-cells in the adult pancreas. *Diabetes* **2005**, *54*, 2586–2595.

48. Stoffers, D.A.; Ferrer, J.; Clarke, W.L.; Habener, J.F. Early-onset type-II diabetes mellitus (MODY4) linked to IPF1. *Nat. Genet.* **1997**, *17*, 138–139.
49. Macfarlane, W.M.; Frayling, T.M.; Ellard, S.; Evans, J.C.; Allen, L.I.S.; Bulman, M.P.; Ayres, S.; Shepherd, M.; Clark, P.; Millward, A.; et al. Missense mutations in the insulin promoter factor-1 gene predispose to type 2 diabetes. *J. Clin. Investig.* **1999**, *104*, R33–R39.

50. Hani, E.H.; Stoffers, D.A.; Chevre, J.-C.; Durand, E.; Stanojevic, V.; Dina, C.; Haebener, J.F.; Froguel, P. Defective mutations in the insulin promoter factor-1 (IPF-1) gene in late-onset type 2 diabetes mellitus. *J. Clin. Investig.* **1999**, *104*, R41–R48.

51. Clocquet, A.R.; Egan, J.M.; Stoffers, D.A.; Muller, D.C.; Wideman, L.; Chin, G.A.; Clarke, W.L.; Hanks, J.B.; Habener, J.F.; Elahi, D. Impaired insulin secretion and increased insulin sensitivity in familial maturity-onset diabetes of the young 4 (insulin promoter factor 1 gene). *Diabetes* **2000**, *49*, 1856–1864.

52. Weng, J.; Macfarlane, W.M.; Lehto, M.; Gu, H.F.; Shepherd, L.M.; Ivarsson, S.A.; Wibell, L.; Smith, T.; Groop, L.C. Functional consequences of mutations in the MODY4 gene (IPF1) and coexistence with MODY3 mutations. *Diabetologia* **2001**, *44*, 249–258.

53. Naya, F.J.; Stellrecht, C.M.M.; Tsai, M.-J. Tissue-specific regulation of the insulin gene by a novel basic helix-loop-helix transcription factor. *Genes Dev.* **1995**, *9*, 1009–1019.

54. Sharma, A.; Stein, R. Glucose-induced transcription of the insulin gene is mediated by factors required for β-cell-type-specific expression. *Mol. Cell. Biol.* **1994**, *14*, 871–879.

55. German, M.S.; Wang, J. The insulin gene contains multiple transcriptional elements that respond to glucose. *Mol. Cell. Biol.* **1994**, *14*, 4067–4075.

56. Grapin-Botton, A.; Majithiam, A.R.; Melton, D.A. Key events of pancreas formation are triggered in gut endoderm by ectopic expression of pancreatic regulatory genes. *Genes Dev.* **2001**, *15*, 444–454.

57. Schwitzgebel, V.M.; Scheel, D.W.; Connors, J.R.; Kalamaras, J.; Lee, J.E.; Anderson, D.J.; Sussel, L.; Johnson, J.D.; German, M.S. Expression of neurogenin3 reveals an islet cell precursor population in the pancreas. *Development* **2000**, *127*, 3533–3542.

58. Gradwohl, G.; Dierich, A.; LeMeur, M.; Guillemot, F. *neurogenin3* is required for the development of the four endocrine cell lineages of the pancreas. *Proc. Natl. Acad. Sci. USA* **2000**, *97*, 1607–1611.

59. Gu, G.; Dubauskaite, J.; Melton, D.A. Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and distinct from duct progenitors. *Development* **2002**, *129*, 2447–2457.
64. Watada, H. Neurogenin 3 is a key transcription factor for differentiation of the endocrine pancreas. *Endocr. J.* 2004, 51, 255–264.

65. Dominguez-Bendala, J.; Klein, D.; Ribeiro, M.; Ricordi, C.; Inverardi, L.; Pastori, R.; Edlund, H. TAT-mediated neurogenin 3 protein transduction stimulates pancreatic endocrine differentiation *in vitro*. *Diabetes* 2005, 54, 720–726.

66. Sharma, A.; Fusco-DeMane, D.; Henderson, E.; Efrat, S.; Stein, R. The role of the insulin control element and RIPE3b1 activators in glucose-stimulated transcription of the insulin gene. *Mol. Endocrinol.* 1995, 9, 1468–1488.

67. Moran, A.; Zhang, H.-J.; Olson, L.K.; Harmon, J.S.; Poitout, V.; Robertson, R.P. Differentiation of glucose toxicity from beta cell exhaustion during the evolution of defective insulin gene expression in the pancreatic islet cell line, HIT-T15. *J. Clin. Investig.* 1997, 99, 534–539.

68. Matsuoka, T.; Zhao, L.; Artner, I.; Jarrett, H.W.; Friedman, D.; Means, A.; Stein, R. Members of the large Maf transcription family regulate insulin gene transcription in islet beta cells. *Mol. Cell. Biol.* 2003, 23, 6049–6062.

69. Olbrot, M.; Rud, J.; Moss, L.G.; Sharma, A. Identification of β-cell-specific insulin gene transcription factor RIPE3b1 as mammalian MafA. *Proc. Natl. Acad. Sci. USA* 2002, 99, 6737–6742.

70. Kataoka, K.; Han, S.I.; Shioda, S.; Hirai, M.; Nishizawa, M.; Handa, H. MafA is a glucose-regulated and pancreatic β-cell-specific transcriptional activator for the insulin gene. *J. Biol. Chem.* 2002, 277, 49903–49910.

71. Matsuoka, T.; Artner, I.; Henderson, E.; Means, A.; Sander, M.; Stein, R. The MafA transcription factor appears to be responsible for tissue-specific expression of insulin. *Proc. Natl. Acad. Sci. USA* 2004, 101, 2930–2933.

72. Zhang, C.; Moriguchi, T.; Kajihara, M.; Esaki, R.; Harada, A.; Shimohata, H.; Oishi, H.; Hamada, M.; Morito, N.; Hasegawa, K.; et al. MafA is a key regulator of glucose-stimulated insulin secretion. *Mol. Cell. Biol.* 2005, 25, 4969–4976.

73. Kaneto, H.; Matsuoka, T.; Nakatani, Y.; Miyatsuka, T.; Matsuhisa, M.; Hori, M.; Yamasaki, Y. A crucial role of MafA as a novel therapeutic target for diabetes. *J. Biol. Chem.* 2005, 280, 15047–15052.

74. Matsuoka, T.; Kaneto, H.; Stein, R.; Miyatsuka, T.; Kawamori, D.; Henderson, E.; Kojima, I.; Matsuhisa, M.; Hori, M.; Yamasaki, Y. MafA regulates expression of genes important to islet β cell function. *Mol. Endocrinol.* 2007, 21, 2764–2774.

75. Wang, H.; Brun, T.; Kataoka, K.; Sharma, A.J.; Wollheim, C.B. MAFA controls genes implicated in insulin biosynthesis and secretion. *Diabetologia* 2007, 50, 348–358.

76. Weir, G.C.; Laybutt, D.R.; Kaneto, H.; Bonner-Weir, S.; Sharma, A. β-Cell adaptation and decompensation during the progression of diabetes. *Diabetes* 2001, 50, S154–S159.

77. Prentki, M.; Nolan, C.J. Islet β cell failure in type 2 diabetes. *J. Clin. Investig.* 2006, 116, 1802–1812.

78. Poitout, V.; Olson, L.K.; Robertson, R.P. Chronic exposure of βTC-6 cells to supraphysiologic concentrations of glucose decreases binding of the RIPE3b1 insulin gene transcription activator. *J. Clin. Investig.* 1996, 97, 1041–1046.
79. Poitout, V.; Robertson, R.P. Minireview: Secondary beta-cell failure in type 2 diabetes—A convergence of glucotoxicity and lipotoxicity. Endocrinology 2002, 143, 339–342.

80. Evans, J.L.; Goldfine, I.D.; Maddux, B.A.; Grodsky, G.M. Are oxidative stress-activated signaling pathways mediators of insulin resistance and β-cell dysfunction? Diabetes 2003, 52, 1–8.

81. Gorogawa, S.; Kajimoto, Y.; Umayahara, U.; Kaneto, H.; Watada, H.; Kuroda, A.; Kawamori, D.; Yasuda, T.; Matsuhisa, M.; Yamasaki, Y.; et al. Probucol preserves pancreatic β-cell function through reduction of oxidative stress in type 2 diabetes. Diabetes Res. Clin. Pract. 2002, 57, 1–10.

82. Harmon, J.S.; Stein, R.; Robertson, R.P. Oxidative stress-mediated, post-translational loss of MafA protein as a contributing mechanism to loss of insulin gene expression in glucotoxic beta cells. J. Biol. Chem. 2005, 280, 11107–11113.

83. Ihara, Y.; Toyokuni, S.; Uchida, K.; Odaka, H.; Tanaka, T.; Ikeda, H.; Hiai, H.; Seino, Y.; Yamada, Y. Hyperglycemia causes oxidative stress in pancreatic β-cells of GK rats, a model of type 2 diabetes. Diabetes 1999, 48, 2398–2406.

84. Kaneto, H.; Matsuoka, T.; Nakatani, Y.; Kawamori, D.; Miyatsuka, T.; Matsuhisa, M.; Yamasaki, Y.; et al. Induction of glycation suppresses glucokinase gene expression in HIT-T15 cells. J. Biol. Chem. 2001, 276, 31099–31104.

85. Robertson, R.P.; Harmon, J.; Tran, P.O.; Tanaka, Y.; Takahashi, H. Glucose toxicity in β-cells: Type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 2003, 52, 581–587.
93. Tanaka, Y.; Tran, P.O.T.; Harmon, J.; Robertson, R.P. A role of glutathione peroxidase in protecting pancreatic β cells against oxidative stress in a model of glucose toxicity. *Proc. Natl. Acad. Sci. USA* 2002, 99, 12363–12368.

94. Sakai, K.; Matsumoto, K.; Nishikawa, T.; Suefuji, M.; Nakamaru, K.; Hirashima, Y.; Kawashima, J.; Shirotani, T.; Ichinose, K.; Brownlee, M.; et al. Mitochondrial reactive oxygen species reduce insulin secretion by pancreatic β-cells. *Biochem. Biophys. Res. Commun.* 2003, 300, 216–222.

95. Kaneto, H.; Fujii, J.; Myint, T.; Islam, K.N.; Miyazawa, N.; Suzuki, K.; Kawasaki, Y.; Nakamura, M.; Tatsumi, H.; Yamasaki, Y.; et al. Reducing sugar triggers oxidative modification and apoptosis in pancreatic β-cells by provoking oxidative stress through the glycation reaction. *Biochem. J.* 1996, 320, 855–863.

96. Kaneto, H.; Xu, G.; Fujii, N.; Kim, S.; Bonner-Weir, S.; Weir, G.C. Involvement of c-Jun N-terminal kinase in oxidative stress-mediated suppression of insulin gene expression. *J. Biol. Chem.* 2002, 277, 30010–30018.

97. Kawamori, D.; Kajimoto, Y.; Kaneto, H.; Umayahara, Y.; Fujitani, Y.; Miyatsuka, T.; Watada, H.; Leibiger, I.B.; Yamasaki, Y.; Hori, M. Oxidative stress induces nucleo-cytoplasmic translocation of pancreatic transcription factor PDX-1 through activation of c-Jun N-terminal kinase. *Diabetes* 2003, 52, 2896–2904.

98. Devary, Y.; Gottlieb, R.A.; Lau, L.F.; Karin, M. Rapid and preferential activation of the c-jun gene during the mammalian UV response. *Mol. Cell. Biol.* 1991, 11, 2804–2811.

99. Nose, K.; Shibanuma, M.; Kikuchi, K.; Kageyama, H.; Sakiyama, S.; Kuroki, T. Transcriptional activation of early-response genes by hydrogen peroxide in a mouse osteoblastic cell line. *Eur. J. Biochem.* 1991, 201, 99–106.

100. Matsuoka, T.; Kaneto, H.; Miyatsuka, T.; Yamamoto, T.; Yamamoto, K.; Kato, K.; Shimomura, I.; Stein, R.; Matsuhisa, M. Regulation of MafA expression in pancreatic β-cells in db/db mice with diabetes. *Diabetes* 2010, 59, 1709–1720.

101. Inagaki, N.; Maekawa, T.; Sudo, T.; Ishii, S.; Seino, Y.; Imura, H. c-Jun represses the human insulin promoter activity that depends on multiple cAMP response elements. *Proc. Natl. Acad. Sci. USA* 1992, 89, 1045–1049.

102. Henderson, E.; Stein, R. c-jun inhibits transcriptional activation by the insulin enhancer, and the insulin control element is the target of control. *Mol. Cell. Biol.* 1994, 14, 655–662.

103. Nauck, M.A.; Heimesaat, M.M.; Orskov, C.; Holst, J.J.; Ebert, R.; Creutzfeldt, W. Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. *J. Clin. Invest.* 1993, 91, 301–307.

104. Xu, G.; Kaneto, H.; Laybutt, D.R.; Duivivier-Kali, V.; Trivedi, N.; Suzuma, K.; King, G.L.; Weir, G.C.; Bonner-Weir, S. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: Possible contribution to the impaired incretin effects in diabetes. *Diabetes* 2007, 56, 1551–1558.

105. Kawashima, S.; Matsuoka, T.; Kaneto, H.; Tochino, Y.; Kato, K.; Yamamoto, K.; Yamamoto, T.; Matsuhisa, M.; Shimomura, I. Effect of alogliptin, pioglitazone and glargine on pancreatic β-cells in diabetic db/db mice. *Biochem. Biophys. Res. Commun.* 2011, 404, 534–540.
106. Shu, L.; Matveyenko, A.V.; Kerr-Conte, J.; Cho, J.H.; McIntosh, C.H.; Maedler, K. Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function. *Hum. Mol. Genet.* **2009**, *18*, 2388–2399.

107. Kang, Z.F.; Deng, Y.; Zhou, Y.; Fan, R.R.; Chan, J.C.; Laybutt, D.R.; Luzuriaga, J.; Xu, G. Pharmacological reduction of NEFA restores the efficacy of incretin-based therapies through GLP-1 receptor signalling in the beta cell in mouse models of diabetes. *Diabetologia* **2013**, *56*, 423–433.

108. Florez, J.C.; Jablonski, K.A.; Bayley, N.; Pollin, T.I.; de Bakker, P.I.; Shuldiner, A.R.; Knowler, W.C.; Nathan, D.M.; Altshuler, D. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. *N. Engl. J. Med.* **2006**, *355*, 241–250.

109. Saxena, R.; Gianniny, L.; Burtt, N.P.; Lyssenko, V.; Giuducci, C.; Sjögren, M.; Florez, J.C.; Almgren, P.; Isomaa, B.; Orho-Melander, M.; *et al.* Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in non-diabetic individuals. *Diabetes* **2006**, *55*, 2890–2895.

110. Horikoshi, M.; Hara, K.; Ito, C.; Nagai, R.; Froguel, P.; Kadowaki, T. A genetic variation of the transcription factor 7-like 2 gene is associated with risk of type 2 diabetes in the Japanese population. *Diabetologia* **2007**, *50*, 747–751.

111. Lyssenko, V.; Lupi, R.; Marchetti, P.; Lyssenko, V.; Lupi, R.; Marchetti, P.; del Guerra, S.; Orho-Melander, M.; Almgren, P.; Sjögren, M.; *et al.* Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. *J. Clin. Investig.* **2007**, *117*, 2155–2163.

112. Boj, S.F.; van Es, J.H.; Huch, M.; Li, V.S.; José, A.; Hatzis, P.; Mokry, M.; Haegebarth, A.; van den Born, M.; Chambon, P.; *et al.* Diabetes risk gene and Wnt effector Tcf7l2/TCF4 controls hepatic response to perinatal and adult metabolic demand. *Cell* **2012**, *151*, 1595–1607.

113. Villareal, D.T.; Robertson, H.; Bell, G.I.; Patterson, B.W.; Tran, H.; Wice, B.; Polonsky, K.S. TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. *Diabetes* **2010**, *59*, 479–485.

114. Liu, Z.; Habener, J.F. Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation. *J. Biol. Chem.* **2008**, *283*, 8723–8735.

115. Takamoto, I.; Kubota, N.; Nakaya, K.; Kumagai, K.; Hashimoto, S.; Kubota, T.; Inoue, M.; Kajiwara, E.; Katsuyama, H.; Obata, A.; *et al.* TCF7L2 in mouse pancreatic beta cells plays a crucial role in glucose homeostasis by regulating beta cell mass. *Diabetologia* **2014**, *57*, 542–553.

116. Mitchell, R.K.; Mondragon, A.; Chen, L.; McGinty, J.A.; French, P.M.; Ferrer, J.; Thorens, B.; Hodson, D.J.; Rutter, G.A.; Xavier, G.D. Selective disruption of Tcf7l2 in the pancreatic β cell impairs secretory function and lowers β cell mass. *Hum. Mol. Genet.* **2015**, *24*, 1390–1399.

© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).